« Previous | Next » | All Messages |  CVBT Message Board Home | recommend post |  Ignore Poster

CVBT News CardioVascular BioTherapeutics Seeks Listing on the AIM Market of the London Stock Exchange

LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) has today announced that it is seeking to list its shares on the London Stock Exchange’s Alternative Investment Market, or “AIM.”

CardioVascular BioTherapeutics is a US biopharmaceutical company, headquartered in Las Vegas, Nevada. It is listed on the OTCBB in the US. The Company was founded in 1998 and has a current market capitalization of $254 million. The proposed admission to AIM is expected to enhance CVBT’s visibility in the marketplace and provide investors and institutions with a more convenient opportunity to invest in the Company.

CVBT is focused on the development of protein-based drugs for the treatment of cardiovascular disease. Its drug candidates are formulated with Cardio Vascu-Grow™ as the active ingredient. CVBT’s Cardio Vascu-Grow™ contains a protein member of the fibroblast growth factor family designed to stimulate the growth and multiplication of blood vessels in a process called angiogenesis. The general principle is that once blood perfusion is increased in the affected areas, patients with cardiovascular diseases may experience an improvement in tissue repair and function.

Daniel C. Montano, president and CEO of CardioVascular BioTherapeutics, said,

“Having a London listing represents a natural ‘next phase’ in CardioVascular BioTherapeutic’s strategic development. In addition, we feel the proposed AIM listing will open up a number of opportunities for the Company.”

Grant Gordon, vice chairman of CardioVascular BioTherapeutics, commented,

“This is an important milestone for the business. We have built good relationships with a range of institutional investors who are interested in the Company. However, until now, they have not had the opportunity to purchase shares through a European market. By seeking to admit the shares to AIM, we believe we will widen our investor base, as we seek to drive the next phase of our growth.”

Zimmerman, Adams International of London, England has been retained by CardioVascular BioTherapeutics to act as its Nominated Adviser for the AIM listing.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow^TM as the active ingredient for treatment of a number of diseases characterized by inadequate blood flow to a tissue or organ. Currently, the company is conducting three FDA-authorized clinical trials: one targeting coronary artery disease in no-option heart patients, a second in the area of impaired dermal wound healing, and the third in patients with peripheral artery disease. In addition, the company has initiated a clinical trial in Russia examining the potential of Cardio Vascu-Grow^TM to improve symptoms in patients with chronic back pain believed to be caused by impaired or blocked lumbar arteries. The Company has also recently completed pre-clinical studies with Cardio Vascu-Grow^TM demonstrating efficacy in animal models of stroke recovery.

Cardio Vascu-Grow^TM is a trademark of CardioVascular BioTherapeutics, Inc.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the Company's most recent documents filed with the Securities and Exchange Commission.